亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101)

医学 吉西他滨 内科学 危险系数 特加福 阶段(地层学) 临床终点 胃肠病学 肺癌 佐剂 肿瘤科 辅助治疗 不利影响 置信区间 外科 癌症 临床试验 生物 古生物学
作者
Masafumi Yamaguchi,Hirohito Tada,Tetsuya Mitsudomi,Takashi Seto,Kohei Yokoi,Nobuyuki Katakami,Kazuhiko Nakagawa,Makoto Oda,Mitsunori Ohta,Toshiyuki Sawa,Motohiro Yamashita,Norihiko Iked,Hideo Saka,Masahiko Higashiyama,Hiroaki Nomori,Hiroshi Semba,Shunichi Negoro,Yasutaka Chiba,Mototsugu Shimokawa,Masahiro Fukuoka,Yoichi Nakanishi
出处
期刊:International Journal of Clinical Oncology [Springer Science+Business Media]
卷期号:26 (12): 2216-2223 被引量:6
标识
DOI:10.1007/s10147-021-02012-9
摘要

Adjuvant oral uracil-tegafur (UFT) has led to significantly longer postoperative survival among patients with non-small-cell lung cancer (NSCLC). Gemcitabine (GEM) monotherapy is also reportedly effective for NSCLC and has minor adverse events (AEs). This study compared the efficacy of GEM- versus UFT-based adjuvant regimens in patients with completely resected pathological stage (p-stage) IB–IIIA NSCLC. Patients with completely resected p-stage IB–IIIA NSCLC were randomly assigned to GEM or UFT. The primary endpoint was overall survival (OS); secondary endpoints were disease-free survival (DFS), and AEs. We assigned 305 patients to the GEM group and 303 to the UFT group. Baseline factors were balanced between the arms. Of the 608 patients, 293 (48.1%) had p-stage IB disease, 195 (32.0%) had p-stage II disease and 121 (19.9%) had p-stage IIIA disease. AEs were generally mild in both groups, and only one death occurred, in the GEM group. After a median follow-up of 6.8 years, the two groups did not significantly differ in survival: 5 year OS rates were GEM: 70.0%, UFT: 68.8% (hazard ratio 0.948; 95% confidence interval 0.73–1.23; P = 0.69). Although GEM-based adjuvant therapy for patients with completely resected stage IB–IIIA NSCLC was associated with acceptable toxicity, it did not provide longer OS than did UFT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
林子青完成签到,获得积分10
14秒前
核桃发布了新的文献求助30
23秒前
李健应助reerwt采纳,获得10
31秒前
32秒前
ICSSCI发布了新的文献求助10
37秒前
40秒前
刘宇童给刘宇童的求助进行了留言
42秒前
reerwt发布了新的文献求助10
46秒前
48秒前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
ICSSCI完成签到,获得积分10
1分钟前
1分钟前
董可以发布了新的文献求助10
1分钟前
风华正茂完成签到,获得积分10
2分钟前
2分钟前
2分钟前
jimmy_bytheway完成签到,获得积分0
2分钟前
桃桃发布了新的文献求助10
2分钟前
可爱的函函应助桃桃采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
3分钟前
NexusExplorer应助科研通管家采纳,获得10
3分钟前
所所应助爱笑的毛衣采纳,获得10
3分钟前
3分钟前
3分钟前
duan完成签到 ,获得积分10
3分钟前
holder完成签到,获得积分10
4分钟前
4分钟前
沐白发布了新的文献求助10
4分钟前
4分钟前
刘宇童发布了新的文献求助10
4分钟前
大模型应助吕易巧采纳,获得10
4分钟前
迷人问兰完成签到,获得积分10
4分钟前
闪闪映易完成签到 ,获得积分10
4分钟前
4分钟前
吕易巧发布了新的文献求助10
4分钟前
吕易巧完成签到,获得积分10
4分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990049
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256354
捐赠科研通 3270976
什么是DOI,文献DOI怎么找? 1805166
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228